Login
$EDSA
$1.89 -$0.05 (2.84%) Live

$EDSA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 SCHEDULE 13G
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

TORONTO and TOKYO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, and KYORIN Pharmaceuti...

05 Nov 2026 Form 4: Nijhawan Pardeep, Director

Received 18,677 shares as a grant or award

04 Nov 2026 SCHEDULE 13G/A
29 Oct 2026 Form 4: Nijhawan Pardeep, Director

Received 27,602 shares as a grant or award

23 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Oct 2026 8-K: Other Events

On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitilig...

06 Oct 2026 Form 4: Nijhawan Pardeep, Director

Received 6,893 shares as a grant or award

01 Sep 2026 Form 4: Nijhawan Pardeep, Director

Received 5,714 shares as a grant or award

26 Aug 2026 SCHEDULE 13G
25 Aug 2026 SCHEDULE 13D/A
25 Aug 2026 SCHEDULE 13D/A
20 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase up to 675,000 Common Shares,

20 Aug 2026 424B5
19 Aug 2026 424B5
13 Aug 2026 FORM 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results ...

04 Aug 2026 Form 4: Nijhawan Pardeep, Director

Received 5,324 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support